Author Archives: Bruno Quinney

Herpes virus cells
#Clinical trial #Herpes virus

Aicuris announces Phase III trial results of HSV treatment

Biotechnology company Aicuris Anti-Infective Cures AG has announced its Phase III trial of pritelivir, a treatment for Herpes Simplex Virus (HSV), has reached its primary endpoint.  The first-in-class helicase primase inhibitor met its primary endpoint of superiority (p=0.0047) in lesion healing in HSV patients receiving treatment up to 28 days. Statistical superiority… Read More

#News

#10x Genomics #Bioscience #Collaboration #SPT Labtech

SPT Labtech and 10x Genomics partner on automated workflows

Manufacturer SPT Labtech has announced a partnership with biotechnology company 10x Genomics to provide automated workflows for single cell research.   The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform, with planned future expansion to the Visium Spatial platform, by providing plug-and-play protocols on SPT Labtech’s… Read More

#Business & Investment #News

Parkinson's disease
#Financing #Mission Therapeutics #Parkinson's

Mission Therapeutics raises $13.3 million for Parkinson’s treatment

Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential process cells use… Read More

#Business & Investment #News

Leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Clinical trial

Amphista Therapeutics nominates AML candidate for clinical trial

Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML).  AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the… Read More

#News

#Antibody drug conjugate (ADC) #Molecular glue degrader #Oncology

Are DACs the new ADCs?

DDW Editor Reece Armstrong speaks to SJ Lee, Founder and CEO of Orum Therapeutics, about the potential of degrader-antibody conjugates (DACs) in treating previously “undruggable” diseases.   RA: How do DACs work? SL: Degrader-antibody conjugates (DACs) combine two proven concepts—antibody precision and catalytic protein degradation—into a single, modular medicine. First, a… Read More

#Exclusive Content

Lipid nanoparticle mRNA vaccine
#Cancer research #Cancer vaccine #University of Massachusetts

Nanoparticle-based vaccine could prevent cancer tumours

A nanoparticle-based vaccine developed by the University of Massachussets Amherst could effectively prevent melanoma, pancreatic and triple-negative breast cancer, the university reveals.  Scientists tested the vaccine in mice, with 88% remaining tumour-free. The results also show that the vaccine reduced, and in some cases prevented, the spread… Read More

#News

India on globe
#Drug development #Drug discovery #India #Investment

Syngene International commits new investment to drug discovery

Syngene International has announced new investment in peptide laboratory and advanced automation to accelerate drug discovery and development in India.  The investments include a dedicated peptide laboratory in Bengaluru and the integration of automation across Drug Metabolism and Pharmacokinetics (DMPK) and Direct-to-Biology (D2B) workflows in Hyderabad. The company hopes the… Read More

#Business & Investment #News

#DNA #Drug therapy #Mitochondria

Drug therapies could prevent hereditary diseases, study finds

New drug therapies could be developed to prevent hereditary diseases, research reveals.  According to a study published in the latest issue of Science, researchers have pinpointed a cellular mechanism involved in the inheritance of genetic mutations. It is believed the findings could help develop treatments… Read More

#News

Ovarian cancer cells
#Antibody drug conjugate (ADC) #Cancer research #Financing

Tubulis raises record $361 million to develop ADC candidate TUB-040

Biotechnology company Tubulis has announced it has raised a record $361 million in financing to expand its clinical development of the antibody-drug conjugate (ADC) candidate TUB-040.  The financing represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally. The financing… Read More

#Business & Investment #News

Prostate cancer cells
#Cancer research #Prostate cancer

Major study into prostate cancer offers hope for new treatments 

New research uncovering a vulnerability in prostate cancer cells could provide ways to improve treatments for prostate cancer.  A major international study, led by scientists from Flinders University in Australia and South China University of Technology, revealed that two enzymes, PDIA1 and PDIA5, play a… Read More

#News

#Drug discovery #Genetics / genomics #Genome sequencing #Gut microbiome #Microbiology

Four therapeutic frontiers opened up by strain-level microbiome sequencing

Dr Jeremy Wilkinson, Microbial Genomics Lead, PacBio, explores how genomics are enabling higher-resolution microbiome profiling and highlights four therapeutic areas where this new layer of genomic precision is beginning to shape drug discovery and development.  Over the past decade, the gut microbiome has gone from a scientific curiosity to a… Read More

#Exclusive Content

Human cell
#AI / data analytics / healthtech / informatics #bit bio #CAR-T #Cell therapy #Data security #Stem cells

New podcast: Overcoming barriers to patient access

This is the latest episode of the free DDW narrated podcast, titled “Overcoming barriers to patient access”, which covers two articles written for DDW Volume 25 – Issue 1, Winter 2023/24. They are called: “Scaling up: The need for human cells to give better access to cell therapies” and… Read More

#News

Human cell
#Narrated podcasts

Overcoming barriers to patient access

This is the latest episode of the free DDW narrated podcast, titled “Overcoming barriers to patient access”, which covers two articles written for DDW Volume 25 – Issue 1, Winter 2023/24. They are called: “Scaling up: The need for human cells to give better access to cell… Read More

#Featured Podcasts #Podcasts

#Alzheimer's #Neuroscience

The promise of gene therapies in Alzheimer’s 

DDW Editor Reece Armstrong speaks to Brian Head, Professor of Anesthesiology at UC San Diego School of Medicine and Veterans Affairs Research Career Scientist, about challenges in Alzheimer's drug discovery and how gene therapy research could provide promise for this challenging treatment area.     RA: Why are early-stage, preventative treatments… Read More

#Exclusive Content

#China #NMPA #Shingles

NMPA approves shingles vaccines in China

The China National Medical Products Association (NMPA) has approved Shingrix for the prevention of shingles. Shingrix has been approved for the prevention of virus in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression.  Shingles is caused by the reactivation of… Read More

#News #Regulatory

Breast cancer cell
#Breast cancer

First patient dosed with breast cancer treatment ABY-271

The first patient has been dosed in a Phase I clinical trial of breast cancer treatment ABY-271. ABY-271 is a radiotherapeutic candidate being assessed as a potential treatment for HER2-positive metastatic breast cancer. The Phase I study evaluating the safety, tolerability and biodistribution of ABY-271 is a first-in-human… Read More

#News